Bain – Global Healthcare Private Equity Report, 2024

The Bain Global Healthcare Private Equity Report for 2024 highlights the challenges faced by the healthcare industry due to macroeconomic factors. Despite these challenges, there are positive signs of growth in deal activity, indicating the strong underlying fundamentals of the industry. Investors are facing difficulties in raising capital for healthcare deals in a challenging fundraising environment. However, they are actively seeking opportunities to unlock liquidity and raise capital for healthcare investments. Biopharma deals make up the largest share of healthcare buyouts, along with deals involving related services such as contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs). These deals continue to dominate the global healthcare deal landscape. In addition, the report highlights the significance of innovative therapies such as GLP-1s in transforming the investment landscape. The rise of these new modalities presents opportunities for investors to diversify their Asia-Pacific buyout activity, with India emerging as a promising market to deploy healthcare capital at scale. Furthermore, private equity investors are increasingly targeting healthcare IT deals, facing competition from tech specialists and corporate investors in this space. The importance of next-generation IT in healthcare is underscored by the deals for electronic medical and health record providers. Overall, the healthcare sector remains a hub of private equity deal activity, despite global challenges such as higher interest rates, inflationary pressures, and geopolitical uncertainty. The report predicts continued growth in the sector, driven by biopharma deals, innovative therapies, and healthcare IT investments.